Maternal type 1 diabetes causes heart defects.

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Maternal type 1 diabetes causes heart defects.

Latest News

Lutikizumab Improves HS Pain, Flares in Phase 3 INTREPID Study

Why Dermatologists Should Stay Involved in Advanced Cutaneous SCC Shannon C. Trotter, DO

Nonsurgical Skin Cancer Care and New Approvals, With Todd Schlesinger, MD

Daxdilimab Improves Discoid Lupus in Phase 2, With Victoria Werth, MD Victoria Werth, MD

5-Year ADlong Data on Lebrikizumab for Eczema, With Stephan Weidinger, MD, PhD

Bitopertin Meets All Endpoints in Phase 3 APOLLO Trial for EPP

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Latest News

News All Time

Nemolizumab Safety, Real-World Use in AD, With Matthias Augustin, MD Matthias Augustin, MD

No Signal for Birth Defects in Dupilumab Pregnancy Registry, With Tina Chambers, PhD, MPH Christina Chambers, PhD, MPH

Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD Iltefat Hamzavi, MD

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Nemolizumab Sustains AD Response at 3 Years, With Matthias Augustin, MD Matthias Augustin, MD

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Upadacitinib Feasible for Palmoplantar Pustulosis: David Gleeson, BM BCH David Gleeson, BM BCH

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Navigating Corticosteroid Stewardship in Dermatology, With Kristina Derrick, MD Kristina Derrick, MD

Denifanstat Sustains Acne Control Through 52 Weeks, With Neal Bhatia, MD Neal Bhatia, MD

Moving Corticosteroid Stewardship into Policy, With Killian Lozach, MBA Killian Lozach, MBA

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

Conference Preview: Fall Clinical Dermatology Conference 2026

Recommended News For You

In patients with prostate cancer, second-generation antiandrogens may worsen fatigue, falls, and cognitive decline.

Ultrasound bras; HPV and thyroid cancer; language minimizing adverse events.

Climate change is expected to increase the number of suicide deaths

Tafasitamab-Based Combination Boosts PFS in Relapsed/Refractory Follicular Lymphoma

The diamonds that could find cancer

NIH research cuts leave cancer patient facing hard choice

Scientists call into question safety of potential new anticancer treatment

Recommended Articles For You

Understanding Fibrosarcoma: What You Need to Know

Preventing Venous Thromboembolism During Hematologic Cancer Care

Understanding Odontogenic Keratocyst: Symptoms, Causes, and Treatments from Dental Experts

Precision Oncology Using Tumor Evolutionary Trajectory Modeling

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.